Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A

Turoctocog alfa is the first B-domain-truncated third generation recombinant coagulation factor VIII (FVIII) product. Nonclinical in vitro and animal model studies have demonstrated that turoctocog alfa has similar functional potency and hemostatic efficacy as comparator FVIII products. With respect...

Descripción completa

Detalles Bibliográficos
Autores principales: Takedani, Hideyuki, Hirose, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378277/
https://www.ncbi.nlm.nih.gov/pubmed/25848213
http://dx.doi.org/10.2147/DDDT.S57967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378277/
https://www.ncbi.nlm.nih.gov/pubmed/25848213
http://dx.doi.org/10.2147/DDDT.S57967

Ejemplares similares